Preclinical imaging / Multi-modality non-invasive biomedical imaging

Daniel Christiaen, Antonio Servadio

Animascope Sarl
ZA Eurekalp
38660 St Vincent de Mercuze (Grenoble), France
Tel: +33 4 76979487
Fax: +33 9 55753911
Email: info@animascope.eu
Website: http://www.animascope.eu/

Non-invasive imaging allows the visualization of structures, functions and dysfunctions in the whole body, in vivo or ex vivo, for research purposes.

Non-invasive imaging allows the visualisation of structures, functions and dysfunctions in the whole body, for research purposes.

In vivo imaging has become a cornerstone in clinical and preclinical studies. Non-invasive technologies facilitate studies of structures, functions and dysfunctions through real-time acquisition, processing and quantification of whole-body images.

Preclinical imaging is suitable for phenotyping, for model validation and for biodistribution studies, as well as for assessment of drug.

Medical imaging is applicable to dynamic biodistribution and biomarker validation studies, and is also used to assess the delivery, liberation, efficacy and safety of drugs, biologics, biopharmaceuticals, nanoparticles, biomaterials and stem cells. Imaging can assist in risk assessment and reproductive toxicology of various safety and efficacy in several therapeutic fields. Non-invasive in vivo imaging is a cost and time-effective approach to streamline R&D and increase predictability of clinical outcomes. With multi-modality imaging, multiple experimental readouts (anatomy, biodistribution, efficacy, safety and kinetics) are available within the frame of the same study, in the same anatomical context. Whole-body studies are performed within days.

Whole-body multimodality studies can be performed on healthy and disease animal models, in many species. (Image courtesy of Siemens Molecular Imaging.)

Biomedical image acquisition, processing and analysis, protocol design and turnkey services

Animascope offers a range of services, including protocol design, image acquisition, image processing, image analysis and reporting. Whole body studies are performed on healthy and disease animal models, in many species. Moreover, Animascope assists in model sourcing and pre-conditioning. Consultancy and training services are also available, to offer turnkey services to international customers.

In vivo imaging

In biomedical research in vivo imaging is applicable to exploratory research, and bridges the gap between preclinical and clinical research. Imaging is particularly useful for pathophysiology, phenotyping and model validation studies.

Imaging in therapeutic fields

Imaging is applicable to several systems and in many therapeutic areas:

infectious diseases
musculoskeletal diseases
cardiovascular diseases
cell therapy and gene therapy
immunization
metabolism
neurology
nutrition (nutraceuticals, dietary supplements and functional food)
oncology
nephrology and genitourinary diseases
reproduction and development

Studies on physiopathology of bones and bones metastasis.

Multidisciplinary expertise and several years of practice are needed to develop effective capabilities in non-invasive biomedical 3D imaging exploratory research. At Animascope, expertise and access to technologies are readily available.

Non-invasive 3D imaging techniques and facilities

Animascope specializes in Magnetic Resonance Imaging (MRI), Ultrasound Imaging (US), X-ray Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Optical Imaging.

Non-invasive 3D-imaging techniques such as X-ray computed tomography (CT) for studies of hard and soft tissues.

Animascope has direct access to imaging platforms in Rhone-Alpes. The Animascope's operating place is in Archamps (Haute Savoie, France) 5 km from Geneva, in the Technopole of Archamps.

Print this page

Edited by Aldo Campana,